BioCentury
DATA GRAPHICS | Product Development

Data Bytes: NASH pipeline still full despite high-profile setbacks

August 28, 2020 12:40 AM UTC

NASH is still any company’s game after two of the most advanced candidates experienced setbacks this year, and both the programs have candidates behind them in their classes: FXR inhibitors and PPAR ɑ/ƍ agonists.

In June, FDA issued a complete response letter for the most advanced NASH candidate, Ocaliva obeticholic acid from Intercept Pharmaceuticals Inc. (NASDAQ:ICPT). The setback came a month after elafibranor from Genfit S.A. (Euronext:GNFT; NASDAQ:GNFT) missed the primary endpoint in the Phase III RESOLVE-IT trial (see “Intercept: Surrogate Endpoint Not Enough”)...